Repatha Dosing and Administration for High Cholesterol
For adults with established cardiovascular disease or primary hyperlipidemia, administer Repatha (evolocumab) 140 mg subcutaneously every 2 weeks OR 420 mg once monthly, with both regimens providing equivalent LDL-C reduction of approximately 55-60%. 1
Dosing by Clinical Indication
Adults with ASCVD or Primary Hyperlipidemia
- Standard dosing: 140 mg SC every 2 weeks OR 420 mg SC once monthly 1
- Both regimens reduce LDL-C by approximately 64% (140 mg Q2W) and 58% (420 mg monthly) 2
- If switching between regimens, give the first dose of the new regimen on the next scheduled date of the prior regimen 1
Pediatric Patients (≥10 years) with Heterozygous Familial Hypercholesterolemia
- Same dosing as adults: 140 mg SC every 2 weeks OR 420 mg once monthly 1
- Demonstrated 44.5% LDL-C reduction at 24 weeks in pediatric trials 3
Homozygous Familial Hypercholesterolemia (Adults and Pediatric ≥10 years)
- Initial dose: 420 mg SC once monthly 1
- Dose escalation: Increase to 420 mg every 2 weeks if clinically meaningful response not achieved after 12 weeks 1
- Patients on apheresis: May initiate 420 mg every 2 weeks to align with apheresis schedule; administer AFTER apheresis session is complete 1
Administration Technique
Injection sites: Rotate between abdomen, thigh, or upper arm 1
Preparation:
- Allow to warm to room temperature for at least 30 minutes (autoinjector/syringe) or 45 minutes (on-body infusor) if refrigerated 1
- Visually inspect: should be clear to opalescent, colorless to pale yellow
- Do not use if cloudy, discolored, or contains particles 1
For 420 mg dose: Either use prefilled single-dose on-body infusor OR give 3 consecutive 140 mg injections within 30 minutes 2
Critical caveat: Some presentations contain dry natural rubber (latex derivative) in needle cover—prescribe latex-free presentations for latex-sensitive patients 1
Monitoring and Response Assessment
LDL-C monitoring:
- Measure as early as 4 weeks after initiation 1
- For monthly dosing, LDL-C can vary during the dosing interval—measure just prior to next scheduled dose for most accurate assessment 1
- Peak LDL-C reduction occurs approximately 1 week after 140 mg Q2W and 2 weeks after 420 mg monthly 4
Expected outcomes:
- Real-world data shows 63.9% LDL-C reduction within first 3 months 5
- Up to 61% of patients achieve LDL-C <55 mg/dL by 10-12 months 5
- Effects sustained long-term with 56-57% LDL-C reduction maintained through 5 years 6
Missed Dose Management
If missed within 7 days: Administer immediately and resume original schedule 1
If missed >7 days:
- For Q2W dosing: Wait until next scheduled dose on original schedule
- For monthly dosing: Administer dose and start new schedule based on this date 1
Clinical Context and Cardiovascular Outcomes
Cardiovascular benefit: The FOURIER trial demonstrated that evolocumab reduced major adverse cardiovascular events (CV death, MI, stroke, revascularization, or hospitalization for unstable angina) with hazard ratio 0.85 (95% CI 0.79-0.92, p<0.001) over 2.2 years median follow-up 7. The key secondary endpoint of CV death, MI, or stroke was reduced by 20% (HR 0.80) 7.
Safety profile:
- Comparable adverse event rates to placebo except injection site reactions (2.1% vs 1.6%) 7
- No increase in cognitive adverse effects 2
- Real-world persistence rates >90% with low discontinuation rates (3.2-5.7%) 8, 6
- No neutralizing antibodies detected in long-term studies 6
Common Pitfalls to Avoid
Don't underdose HoFH patients: If inadequate response at 12 weeks on 420 mg monthly, escalate to 420 mg every 2 weeks rather than accepting suboptimal control 1
Timing with apheresis: Always administer AFTER apheresis is complete, not before 1
Latex sensitivity: Verify patient latex allergy status and prescribe appropriate formulation 1
Monitoring timing: For monthly dosing, avoid measuring LDL-C mid-cycle as levels fluctuate—measure just before next dose 1